LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Feb 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-02-10

Reporting Person: Davis Todd C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-10	Common Stock	S	5083	$213.1438	Disposed	47678	Direct
2021-02-11	Common Stock	M	2474	$195.91	Acquired	50152	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-11	Non-Qualified Stock Option (right to buy)	$195.91	M	2474	Disposed	2028-06-18	Common Stock (2474)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.84 to $214.58, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.